Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
Wednesday, $Abbott Laboratories (ABT.US)$ reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion.
星期三， $雅培 (ABT.US)$ 公布的第一季度销售额为99.6亿美元，基础业务的有机增长10.8％，超过市场普遍预期的98.8亿美元。
Reported sales increased by 2.2%, which includes the anticipated decline in COVID-19 testing-related revenue compared to the previous year.
报告的销售额增长了2.2％，其中包括与去年相比COVID-19 测试相关收入的预期下降。
First-quarter growth was led by Medical Devices (up 14.3% organic; 14.2% reported), with FreeStyle Libre sales growing 23.3% on an organic basis (22.4% reported) to $1.5 billion.
第一季度增长由医疗器械带动（有机增长14.3％；报告为14.2％），FreeStyle Libre的销售额有机增长23.3％（报告为22.4％），达到15亿美元。
Additional growth came from Established Pharmaceuticals (up 13.7% organic; 3.1% reported), Nutrition (up 7.7% organic; 5.1% reported), and Diagnostics (up 5.4% organic; 2.7% reported).
其他增长来自成熟药业（有机增长13.7％；报告增长3.1％）、营养（有机增长7.7％；报告了5.1％）和诊断（有机增长5.4％；报告了2.7％）。
"Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance," said Robert Ford, chairman and CEO. "This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals."
董事长兼首席执行官罗伯特·福特表示：“我们的第一季度业绩反映了今年的强劲开局，我们正在提高全年销售额和每股收益预期。”“这是我们连续第五个季度实现基础业务的两位数有机销售增长，其中包括医疗器械和成熟药品领域特别强劲的业绩。”
Abbott's adjusted diluted earnings per share was $0.98, beating the analyst estimates of $0.95.
雅培调整后的摊薄后每股收益为0.98美元，超过了分析师预期的0.95美元。
Guidance: For 2024, Abbott revised its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 versus the prior guidance of $4.50-$4.70 and consensus of $4.62.
指导方针：对于2024年，雅培将其2024财年调整后的每股收益预期下调至4.55美元至4.70美元，而之前的预期为4.50美元至4.70美元，共识为4.62美元。
Abbott projects second-quarter adjusted EPS Of $1.08-$1.12 versus the consensus of $1.12.
雅培预计第二季度调整后的每股收益为1.08-1.12美元，而市场普遍预期为1.12美元。
Price Action: ABT shares are down 0.87% at $108.26 during the premarket session on the last check Wednesday.
价格走势：在周三最后一次支票的盘前交易中，ABT股价下跌0.87％，至108.26美元。